Immunicum Aktie

Kaufen

Verkaufen

Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

WKNA1W59F

ISINSE0005003654

Immunicum Aktien News

Sortieren:Datum Meistgelesen

19.03.24GlobeNewswireMendus to present NK cell program progress at the Innate Killer Summit

15.03.24GlobeNewswireMendus’ major shareholders and members of the Board of Directors and Management declare their intention to exercise warrants of series TO3

15.03.24GlobeNewswireThe exercise period for warrants of series TO3 commences today

12.03.24GlobeNewswireMendus provides business update and outlook for vididencel program

27.02.24GlobeNewswireMendus to participate in upcoming industry conferences

23.02.24GlobeNewswireMendus to hold Business Update event on March 12

14.02.24GlobeNewswireMendus AB Year-end Report for 2023

09.02.24GlobeNewswireInvitation to presentation of Mendus’ year-end report for 2023

08.01.24GlobeNewswireMendus to participate in several investor and industry conferences in January

22.12.23GlobeNewswireMendus announces clinical pipeline update

13.12.23GlobeNewswireMendus AB: REPORT FROM THE EXTRAORDINARY GENERAL MEETING OF MENDUS AB (PUBL) ON 13 DECEMBER 2023

11.12.23GlobeNewswireMendus announces positive survival data from Phase 2 ADVANCE II trial evaluating vididencel as maintenance therapy for AML at ASH 2023

06.12.23GlobeNewswireMendus and Australasian Leukaemia & Lymphoma Group to expand clinical testing of vididencel as maintenance treatment for AML

05.12.23GlobeNewswireMendus to present at Cell & Gene Therapy Manufacturing & Commercialization Conference in Dublin on December 4-6

04.12.23GlobeNewswireMendus to Host KOL Event to Review Phase 2 Data with Vididencel in Acute Myeloid Leukemia Presented at ASH 2023 on December 14, 2023

17.11.23GlobeNewswireMendus Announces Nomination Committee for the 2024 Annual General Meeting

13.11.23GlobeNewswireNOTICE OF EXTRAORDINARY GENERAL MEETING IN MENDUS AB (PUBL)

09.11.23GlobeNewswireMendus AB Interim Report January – September 2023

06.11.23GlobeNewswireMendus presents updated ALISON clinical trial data for vididencel in ovarian cancer at SITC 2023

03.11.23GlobeNewswireMendus Phase 1 vididencel clinical trial results in AML and high-risk MDS patients published in peer-reviewed medical journal

02.11.23GlobeNewswireMendus announces multiple abstracts to be presented at ASH 2023 including oral presentation on ADVANCE II survival data

26.10.23GlobeNewswireMendus to participate in several investor and industry conferences in November and to host investor webcast and lunch on November 9

28.09.23GlobeNewswireMendus will participate in multiple investor and industry conferences in October and announces presentation of ALISON trial update at SITC

21.09.23GlobeNewswireMendus to present novel data supporting the broad potential of its proprietary cancer vaccine platform at CICON23

08.09.23GlobeNewswireMendus receives U.S. FDA Fast Track Designation for vididencel in Acute Myeloid Leukemia (AML)

06.09.23GlobeNewswireMendus Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference in September

04.09.23GlobeNewswireMendus to participate in multiple investor and industry conferences in September

31.08.23GlobeNewswireChange in number of shares and votes in Mendus AB (publ)

29.08.23GlobeNewswireMendus AB (publ) Interim Report January – June 2023

16.08.23GlobeNewswireMendus publishes preclinical data demonstrating synergies of ilixadencel and 4-1BB-targeting immunotherapies

28.07.23GlobeNewswireMendus raises approximately SEK 317 million through the directed issue to Flerie and a fully secured rights issue

11.07.23GlobeNewswireMendus publishes prospectus regarding previously announced rights issue and directed issue

10.07.23GlobeNewswireMendus AB: Report from the extraordinary general meeting of Mendus AB (publ) on 10 July 2023

20.06.23GlobeNewswireMendus appoints NK cell pioneer Lewis Lanier to Scientific Advisory Board

Immunicum News

Immunicum News: auf dieser Seite finden Sie alle Immunicum News und Nachrichten zur Immunicum Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Immunicum News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Immunicum News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.